دورية أكاديمية

Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

التفاصيل البيبلوغرافية
العنوان: Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)
المؤلفون: M. Sabaté, X. Vidal, E. Ballarin, M. Rottenkolber, S. Schmiedl, B. Grave, C. Huerta, E. Martin-Merino, D. Montero, L. M. Leon-Muñoz, C. Gasse, N. Moore, C. Droz, R. Lassalle, M. Aakjær, M. Andersen, M. L. De Bruin, P. Souverein, O. H. Klungel, H. Gardarsdottir, L. Ibáñez
المصدر: Frontiers in Pharmacology, Vol 12 (2021)
بيانات النشر: Frontiers Media S.A., 2021.
سنة النشر: 2021
المجموعة: LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: adherence, persistence, anticoagulants, non valvular atrial fibrillation, cardiovascular, drug utilization, Therapeutics. Pharmacology, RM1-950
الوصف: Aims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries.Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008–2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases.Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases.Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH).
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2021.682890/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2021.682890
URL الوصول: https://doaj.org/article/40f7ac33719a4163ae75ab1711be72b0
رقم الأكسشن: edsdoj.40f7ac33719a4163ae75ab1711be72b0
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:16639812
DOI:10.3389/fphar.2021.682890